[Bone turnover markers evaluation in psoriatic arthritis]. 2008

Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
Universitatea de Vest "V. Goldiş" Arad, Facultatea de Medicină, Clinica de Medicină internă - Imunologie, Spitalul Clinic Judeţean Arad.

The aim of this study was to investigate the blood level of bone turnover markers: osteoprotegerin (OPG), bone alkaline phosphatase (Bone-ALP), and receptor activator of NF-kappa B ligand (RANKL) of patients with psoriatic arthritis. METHODS Twenty-four patients with psoriatic arthritis (CASPAR classification criteria) and twenty healthy controls were included. The OPG, Bone-ALP and RANKL levels were quantified by using ELISA method. RESULTS Peripheral blood levels of bone turnover markers were higher in psoriatic arthritis than martors and there was a strong negative correlation between OPG-RANKL and Bone-ALP- RANKL. CONCLUSIONS The OPG and Bone-ALP serum level is strongly negative related to the increase in RANKL serum level in patients with psoriatic arthritis. The increase in OPG and Bone-ALP serum level induces the production of bone matrix parallel to the bone destruction mediated by RANKL. Follow up of patients with psoriatic arthritis, by use of early determination of RANKL, OPG and Bone-ALP serum levels, and also of bone metabolism markers (they have specific role in bone remodeling), allows a precise evaluation of disease activity and, in future, could be a criteria for the initiation of specific, targeting treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
January 2015, The Journal of rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
August 1991, The Journal of rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
April 2008, Clinical rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
May 2013, Australian family physician,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
January 2004, Internal medicine journal,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
December 1989, Clinical rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
May 2013, The Journal of rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
May 2002, The Journal of rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
May 2002, The Journal of rheumatology,
Camelia Ciacli, and Maria Puşchiţă, and Doina Drugărin, and C Solovan, and Camelia Vidita Gurban, and Coralia Cotoraci
December 2019, JAMA,
Copied contents to your clipboard!